AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback